Skip to main content

Table 1 Patient’s characteristics

From: Bifractionated CPT-11 with LV5FU2 infusion (FOLFIRI-3) in combination with bevacizumab: clinical outcomes in first-line metastatic colorectal cancers according to plasma angiopoietin-2 levels

  FOLFIRI3-bevacizumab
(n = 61)
Demographic or clinical characteristics No. of patients %
Male 35 57
Age, years   
  Median 63.6  
  Range 38-81  
ECOG performance status   
  0 25 41
  1 32 52
  2 4 7
Primary tumor type   
  Colon 38 62
  Rectal 23 38
No. of sites involved by metastases   
  1 35 57
  2 19 31
  > = 3 7 12
Site of metastatic disease   
  Liver only 25 41
  Liver + other 20 33
  Other only 16 26
Prior adjuvant chemotherapy   
  All 18 30
  Oxaliplatin-based 15 25
  < 12 months 8 13
Synchronous tumors   
  Yes 39 64
  No 22 36